Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.

Biocartis Idylla™ GeneFusion Panel

Products are for professional/laboratory use only Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1 and RET fusions & MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections from patients with NSCLC.

New Study Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions

Products are for professional/laboratory use only. New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods: